Open Heart

JANUARY 18, 2024

Introduction Three recent randomised controlled trials have demonstrated that pulmonary vein isolation as an initial rhythm control strategy with cryoablation reduces atrial arrhythmia recurrence in patients with symptomatic paroxysmal atrial fibrillation (PAF) compared with antiarrhythmic drug (AAD) therapy.

Atrial Fibrillation 69

Atrial Fibrillation Ablation Pulmonary Arrhythmia 69

Frontiers in Cardiovascular Medicine

JANUARY 31, 2024

Background Pulmonary vein isolation with wide antral ablation leads to better clinical outcomes for the treatment of atrial fibrillation, but the isolation lesion is invisible in conventional cryoballoon ablation. The rate of 12-month freedom from clinical atrial arrhythmia recurrence was 85.1%

Atrial Fibrillation 64

Atrial Fibrillation Ablation Pulmonary Outcomes 64

HeartRhythm

APRIL 30, 2024

Animal studies suggest that catheter ablation-associated parasympathetic and sympathetic denervation could result in increased ventricular arrhythmias (VA). The impact of catheter ablation of atrial fibrillation on VA burden in humans has not been assessed.

Atrial Fibrillation 40

Atrial Fibrillation Arrhythmia Ablation Pulmonary 40

European Journal of Heart Failure

FEBRUARY 25, 2025

Overview of the study population and effects observed after catheter ablation for atrial fibrillation. PVI, pulmonary vein isolation. Herein we describe the effects of catheter ablation on AF burden, arrhythmia recurrences, and ventricular function in end-stage HF. Median AF burden reduction was 36.3

Atrial Fibrillation 40

Atrial Fibrillation Ablation Heart Failure Arrhythmia 40

HeartRhythm

APRIL 30, 2024

Multiple randomized controlled trials (RCTs) have compared the efficacy of pulmonary vein isolation (PVI) adjunctive techniques with PVI alone in patients with persistent atrial fibrillation (AF).

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Arrhythmia 40

Frontiers in Cardiovascular Medicine

JANUARY 15, 2024

Background Catheter ablation (CA) for symptomatic atrial fibrillation (AF) offers the best outcomes for patients. We present real-world 5-year follow-up data of AI-guided pulmonary vein isolation. We present real-world 5-year follow-up data of AI-guided pulmonary vein isolation. Age >75 years ( p  = 0.02, HR: 2.7,

Ablation 64

Ablation Atrial Fibrillation BMI Arrhythmia 64

DAIC

FEBRUARY 2, 2024

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , revealed findings from a company-funded study of real-world data. AFib is the most common type of cardiac arrhythmia and affects more than 6 million people in the United States and nearly 38 million people worldwide.2,3 In: AF Symposium.;

Ablation 105

Ablation Atrial Fibrillation AFIB Heart Rhythm 105

Frontiers in Cardiovascular Medicine

FEBRUARY 7, 2024

Background Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with a high risk of stroke. Conclusion Our findings indicate that an enlarged left atrium and abnormal hemodynamic parameters in the left atrial and pulmonary veins are linked to a greater risk of LAT/SEC.

Atrial Fibrillation 64

Atrial Fibrillation Stroke Strokes Pulmonary 64

Frontiers in Cardiovascular Medicine

FEBRUARY 17, 2025

Backgroundwide antral pulmonary vein isolation (PVI) is effective for treating paroxysmal atrial fibrillation (PAF), although time-demanding. The primary endpoint was achieved by 9% and 12% of cases at 12 and 24 month follow up, respectively.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Laboratory Electrophysiology 52

Dr. Smith's ECG Blog

JANUARY 5, 2020

Here is the computer interpretation: ATRIAL FIBRILLATION WITH RAPID VENTRICULAR RESPONSE WITH ABERRANT CONDUCTION OR VENTRICULAR PREMATURE COMPLEXES LEFT AXIS DEVIATION [QRS AXIS beyone -30] NONSPECIFIC ST and T-WAVE ABNORMALITY The over-reading physician confirmed this diagnosis, which is incorrect. It is not atrial fibrillation.

Atrial Fibrillation 52

Atrial Fibrillation Tachycardia Arrhythmia Pulmonary 52

Journal of Cardiovascular Electrophysiology

MARCH 27, 2025

ABSTRACT Background Ultra-low temperature cryoablation (ULTC) is a technique designed to rapidly cool cardiac tissue to extremely low temperatures, enabling the creation of ablation lesions for the treatment of atrial fibrillation (AF). Arrhythmia outcomes after repeat ablation were evaluated.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Bicuspid/Mitral 40

HeartRhythm

APRIL 30, 2024

Low voltage area (LVA) and low conduction velocity (CV) are promising risk factors to identify patients with abnormal atrial substrate at a high risk of atrial fibrillation (AF) recurrence following pulmonary vein isolation (PVI).

Pulmonary 40

Pulmonary Atrial Fibrillation Arrhythmia Risk Factors 40

Circulation: Arrhythmia and Electrophysiology

NOVEMBER 3, 2023

Circulation: Arrhythmia and Electrophysiology, Volume 16, Issue 11 , Page e012043, November 1, 2023. BACKGROUND:In patients with persistent atrial fibrillation (PersAF), catheter ablation aiming for pulmonary vein isolation (PVI) is associated with moderate clinical effectiveness.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Quality of Life Ablation 40

Journal of Cardiovascular Electrophysiology

APRIL 2, 2025

The Kaplan-Meier curve of all-atrial arrhythmia-free survival for (A) all persistent patients and (B) patients who underwent PSM conducted to the higher recurrence rate in PVI + group. Methods Data from early commercial use across seven European centers were collected in a registry. Procedural and follow-up data were collected.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Tachycardia Tricuspid 40

Circulation: Arrhythmia and Electrophysiology

DECEMBER 19, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Pulmonary vein isolation (PVI) alone is less effective in patients with persistent atrial fibrillation (AF) compared with those with paroxysmal AF. to 3.4%]; hazard ratio, 0.66 [95% CI, 0.460.94]).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Pulmonary 40

Circulation: Arrhythmia and Electrophysiology

JANUARY 29, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:High-power short-duration ablation has shown impressive efficacy and safety for pulmonary vein isolation (PVI); however, initial efficacy results with very high power short-duration ablation were discouraging. ie, noninferiority is met).

Electrophysiology 76

Electrophysiology Atrial Fibrillation Pulmonary Ablation 76

Circulation: Arrhythmia and Electrophysiology

MARCH 21, 2025

Circulation: Arrhythmia and Electrophysiology, Ahead of Print.

Atrial Fibrillation 40

Atrial Fibrillation Electrophysiology Arrhythmia Pulmonary 40

DAIC

DECEMBER 22, 2023

The first procedures were performed by Dr. David Newton , Clinical Cardiac Electrophysiologist at Memorial Health University Physicians Heart Care and Dr. Andrea Natale , Executive Medical Director at T exas Cardiac Arrhythmia Institute, St. David’s Medical Center.

Atrial Fibrillation 59

Atrial Fibrillation AFIB Ablation Heart Rhythm 59

Journal of Cardiovascular Electrophysiology

NOVEMBER 11, 2024

This study of 16 patients with persistent left superior vena cava (PLSVC) undergoing atrial fibrillation ablation shows a 66.7% Abstract Objectives To investigate tailored approaches, techniques, and outcomes of catheter ablation in patients with persistent left superior vena cava (PLSVC) undergoing atrial fibrillation (AF) ablation.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Pulmonary 40

Frontiers in Cardiovascular Medicine

JULY 16, 2024

BackgroundAmiodarone is a class III antiarrhythmic drug that is commonly used in the clinic to treat ventricular arrhythmias and atrial fibrillation.

Atrial Fibrillation 52

Atrial Fibrillation Chest Pain Arrhythmia Pulmonary 52

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Introduction Earlier studies have shown a clear association between severity of human immunodeficiency virus (HIV) infection and incident atrial fibrillation (AF). During first procedure, all received isolation of pulmonary vein (PV) + posterior wall and superior vena cava. vs. 87.1%, p  = .753]

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Arrhythmia 40

Journal of Cardiovascular Electrophysiology

OCTOBER 19, 2023

Although the QDOT MICRO™ Catheter was mainly designed for pulmonary vein isolation (PVI) its versatility to treat atrial fibrillation (AF) and other types of arrhythmias was recently evaluated by the FAST and FURIOUS study series and other studies and will be presented in this article.

Arrhythmia 40

Arrhythmia Ablation Atrial Flutter Atrial Fibrillation 40

HeartRhythm

NOVEMBER 21, 2024

2 BB area pacing defined using P-wave criteria has been associated with decreased atrial arrhythmia burden, recurrence, and de novo incidence compared with right atrial septal pacing and right atrial appendage pacing.3

Pulmonary 40

Pulmonary Atrial Fibrillation Arrhythmia 40

HeartRhythm

FEBRUARY 15, 2024

Pulmonary vein isolation (PVI) has been established as a cornerstone therapy for atrial fibrillation (AF). Despite its effectiveness, over 20% of patients still experience recurrences of AF and atrial tachyarrhythmias (ATs) after PVI.1

Atrial Fibrillation 40

Atrial Fibrillation Arrhythmia Pulmonary Ablation 40

Journal of Cardiovascular Electrophysiology

JANUARY 10, 2024

Abstract Introduction Despite advanced ablation strategies and major technological improvements, treatment of persistent atrial fibrillation (AF) remains challenging and the underlying pathophysiology is not fully understood. After a blanking period of 6 weeks, recurrence of any atrial arrhythmia was documented in 26 patients (52%).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outpatient Arrhythmia 40

HeartRhythm

JANUARY 29, 2024

The role of the right atrium (RA) in atrial fibrillation (AF) has long been overlooked. Multiple studies have examined clinical conditions associated with AF, such as atrial enlargement, fibrosis extent, electrical remodeling, and wall thickening, but have been mainly concentrated on the left atrium (LA).

Arrhythmia 40

Arrhythmia Atrial Fibrillation Pulmonary Research 40

All About Cardiovascular System and Disorders

MAY 18, 2024

Pulsed Field Ablation is a relatively new modality for treatment of atrial fibrillation. In conventional ablation for atrial fibrillation, either heating of tissue is produced by radiofrequency application or freezing of tissues by cryoablation. That was a new analysis of the ADVENT trial [2]. N Engl J Med. May 18, 2024.

Ablation 40

Ablation Atrial Fibrillation Pulmonary Arrhythmia 40

HeartRhythm

JULY 30, 2024

Extra-pulmonary vein (PV) triggers have been reported in up to 4.9-15% 15% of all atrial fibrillation (AF) patients who undergo catheter ablation and plays significant roles in arrhythmia recurrence.1,2

Aneurysm 40

Aneurysm Ablation Atrial Fibrillation Pulmonary 40

Journal of Cardiovascular Electrophysiology

MARCH 6, 2024

This novel cryoballoon with adjustable size and low compliance successfully achieves pulmonary vein isolation to treat paroxysmal atrial fibrillation (PAF), providing more options for patients with PAF. of patients after the 3-month blanking period.

Pulmonary 40

Pulmonary Atrial Fibrillation Outcomes Document 40

Circulation: Arrhythmia and Electrophysiology

DECEMBER 16, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. Each patient was given a mobile device to record a daily ECG and detect atrial tachyarrhythmias.RESULTS:The primary end point, freedom from any atrial tachyarrhythmia recurrence between 91 and 365 days post-catheter ablation, did not significantly differ between the 2 groups (62.9%

Ablation 40

Ablation Atrial Fibrillation Electrophysiology Pulmonary 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Background The newly introduced nonthermal pulsed field ablation (PFA) is a promising technology to achieve fast pulmonary vein isolation (PVI) with high acute success rates and good safety features. Compared to PFA VHPSD-PVI might ensure information on left atrial substrate allowing to target concomitant secondary tachycardias.

Ablation 40

Ablation Pulmonary Arrhythmia Atrial Fibrillation 40

Dr. Smith's ECG Blog

JANUARY 22, 2020

This middle-aged patient presented with SOB, weakness, and mild pulmonary edema. She previously had Atrial fibrillation with LBBB. This shows atrial fibrillation. The fact that the response is regular proves that the atrial fibrillation is NOT conducting. There is a regular, slow response.

Pulmonary 52

Pulmonary AFIB Atrial Fibrillation Pacemaker 52

DAIC

DECEMBER 26, 2023

a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.

Ablation 59

Ablation Atrial Fibrillation Technology Cardiothoracic 59

Dr. Smith's ECG Blog

FEBRUARY 6, 2024

Atrial fibrillation is also a predictor of worse outcomes in this case (Alborzi). Q waves in association with RBBB are usually not seen in anterior leads unless there is pulmonary hypertension or anterior infarction. Other Arrhythmias ( PACs, PVCs, AFib, Bradycardia and AV conduction disorders — potentially lethal VT/VFib ).

Tachycardia 115

Tachycardia Dysrhythmia Atrial Fibrillation Bradycardia 115

Journal of Cardiovascular Electrophysiology

JANUARY 28, 2024

Abstract Introduction During atrial fibrillation ablation (AFA), achievement of first pass isolation (FPI) reflects effective lesion formation and predicts long-term freedom from arrhythmia recurrence. We aim to determine the clinical and procedural predictors of pulmonary vein FPI.

Ablation 40

Ablation Pulmonary BMI Atrial Fibrillation 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 21, 2023

Abstract Introduction Pulmonary vein isolations (PVI) are being performed using a high-power, short-duration (HPSD) strategy. The purpose of this study was to compare the clinical efficacy and safety outcomes of an HPSD versus low-power, long-duration (LPLD) approach to PVI in patients with paroxysmal atrial fibrillation (AF).

Ablation 40

Ablation Pulmonary Atrial Fibrillation Arrhythmia 40

Dr. Smith's ECG Blog

OCTOBER 23, 2023

T-wave alternans and the susceptibility to ventricular arrhythmias. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Both ST segment and T wave alternans have been known to precede malignant ventricular arrhythmias. Pacing Clin Electrophysiol.

Tachycardia 130

Tachycardia Cardiac Arrest ICU Blog 130